Biomarkers for the Prevention of Drug Induced AKI (D-AKI)
|
|
- Eugene McDonald
- 5 years ago
- Views:
Transcription
1 Biomarkers for the Prevention of Drug Induced AKI (D-AKI) Sandra Kane-Gill, PharmD, MSc, FCCM, FCCP Associate Professor, University of Pittsburgh Critical Care Medication Safety Pharmacist, UPMC
2 OBJECTIVE Propose the utility of novel biomarkers for the prevention of D-AKI Disclosures: None
3 WHAT ARE THE IDEAL CHARACTERISTICS OF A BIOMARKER FOR AKI PREVENTION?
4 CHARACTERISTICS OF BIOMARKERS FOR PREVENTION OF AKI/D-AKI IDEAL CHARACTERISTICS 1. Easily measured 2. Present at initiation of disease & earlier than other biomarkers 3. Detect to a greater degree than current biomarkers 4. Unaffected by other diseases/factors 5. Proportional response to severity CURRENT CHARACTERISTICS 1. Urine and serum 2. Major advantage 3.? Accuracy of detection 4. Affected by other diseases; varies by biomarker 5. Proportional to severity depends on biomarker
5 EVIDENCE FROM D-AKI LITERATURE Advantage Urine and serum Presents earlier than current biomarkers Detect to a greater degree Affected by other diseases Severity Example of Evidence NGAL: cisplatin induced nephrotoxicity; 4 of 6 studies positive; more favorable for urine than serum; similar results for KIM-1 NGAL: evaluated amphotericin induced AKI and compared NGAL to SCr; NGAL detected AKI days sooner NGAL: higher for AKI-related to NSAIDs than hypovolemia and type 1 hepatorenal syndrome and lower than acute tubular necrosis NGAL: may be elevated in sepsis, malignancy, CKD, UTIs TIMP-2-IGFBP7: may be elevated in diabetes KIM-1 and NGAL: higher concentration more severe kidney damage TIMP-2-IGFBP7: moderate risk > 0.3 to 2.0 & high > 2.0; also on day one of nephrotoxin administration the biomarker value is higher >0.5 for patients who progress to Stage 2/3 AKI NGAL = Neutrophil gelatinase-associated lipocalin; KIM-1 = kidney injury molecule-; TIMP2-IGFBP-7 = tissue inhibitor of metalloproteinase-insulin like growth factor-binding protein Kane-Gill et al. Drug Saf 2017;40:1049
6 Kashani K, et al. Crit Care 2013;17:R25. Hoste E, et al. Nephrol Dial Transplant 2014;29: Bihorac A, et al. Am J Resp Crit Care Med 2014;189: TIMP-2 IGFBP7 (NEPHROCHECK ) Sapphire study: Discovery and Validation Discovery: 340 proteins; AKI stage II and III in 12 h TIMP2 AUC 0.76; IGFBP7 AUC 0.79; TIMP2-IGFBP7 AUC 0.8 Validation Clinical variables (included SCr): AUC 0.81 Clinical variables + TIMP2-IGFBP7: AUC 0.87 Opal study: Established clinical cut-offs Low risk <0.3 negative predictive value 97% Moderate risk > : 4+ fold higher risk High risk >2.0: 10+ fold higher risk Topaz study Clinical adjudication of AKI (not KDIGO) TIMP2-IGFBP7 better association with clinicians than SCr 12% disagreement- biomarker more often agreed with majority (2 of 3 clinicians)
7 Kashani K, et al. Crit Care 2013;17:R25. Courtesy of Erin Frazee Baretto, PharmD. TIMP-2 IGFBP7 (NEPHROCHECK ) Cell-cycle arrest markers detected in urine Pause in replication to prevent damaged cells from dividing TIMP-2 and IGFBP7 released Kidney sustains an insult (e.g. hypoperfusion) G 1 Phase Mitosis S Phase (DNA Synthesis) G 2 Phase Detected in the urine, signal risk for cell damage and AKI
8 PREVAKI RANDOMIZED CONTROLLED TRIAL Single-center, randomized trial of 276 cardiac surgery patients with TIMP-2 IGFBP control patients 138 intervention patients Primary Endpoint: Any AKI at 72-h Any AKI: 72% Stage II/III: 45% Any AKI: 55% Stage II/III: 30% ACEI/ARB- significantly less Vancomycin, diuretics, contrast and overall nephrotoxins not significantly less KDIGO Bundle Avoid nephrotoxins Withhold ACEI/ARB Monitor SCr/UOP Glucose < 150 mg/dl Limit IV contrast Optimize volume status/hemodynamics Meersch M, et al. Intensive Care Med 2017;43:
9 PREVAKI RANDOMIZED CONTROLLED TRIAL Single-center, randomized trial of 276 cardiac surgery patients with TIMP-2 IGFBP control patients 138 intervention patients Primary Endpoint: Any AKI at 72-h Any AKI: 72% Stage II/III: 45% Any AKI: 55% Stage II/III: 30% KDIGO Bundle Avoid nephrotoxins Monitor SCr/UOP Limit IV contrast Withhold ACEI/ARB Glucose < 150 mg/dl Optimize volume status/hemodynamics We already do this Meersch M, et al. Intensive Care Med 2017;43:
10 BIGPAK RANDOMIZED CONTROLLED TRIAL Single-center, randomized trial of 121 major elective noncardiac surgery patients with 1 risk factor for AKI- screened If TIMP-2 IGFBP7 0.3 randomized 61 control patients 60 intervention patients Primary Endpoint: Any AKI at 7 days Any AKI: 48% Stage II/III: 20% Any AKI: 32% Stage II/III: 7% 35% (n=21) patients had a recommendation for nephrotoxic drug management by nephrologist and 76% changes accepted KDIGO Bundle Avoid nephrotoxins Optimize fluid status Maintain perfusion pressure Nephrology consult Gocze I et al. Annals of Surgery 2017; epub ahead of print.
11 NEPHROCHECK RAPID RESPONSE TEAM Clinical Stratification Low Risk High Risk Very High Risk Monitor & prevent TIMP-2 IGFBP7 nephrology consult Ronco C, et al. Nephrol Dial Transplant 2017;32: Rizo-Topete L et al. 2017;43:82-88 Laboratory Stratification 0.3 > 0.3 to 2.0 > 2.0 Monitor, non-invasive tests, optimize fluid status and perfusion, avoid nephrotoxins, informal nephrology consult Consult Neph., d/c nephrotoxins, optimize perfusion with fluids and vasopressors, consider dialysis
12 WHAT IS THE THEME? Know your AKI rates Also, need an understanding of causes Identify patients at risk for AKI Hypervigilance Surveillance-discussion on each patient Ensuring best practices
13 MANAGING NEPHROTOXINS EARLY WARNING AND HYPERVIGILANCE
14 KINETICS OF URINARY BIOMARKERS(KIM-1, NGAL) AND VANCOMYCIN EXPOSURE Biomarker AUC-ROC 95% CI SCr Day SCr Day SCr Day SCr Day ukim-1 Day ukim-1 Day ukim-1 Day ukim-1 Day ungal Day ungal Day ungal Day ungal Day ukim-1 and ungal Pang HM et al. Eur Rev Med Pharmaocol SCI 2017;21:4203 NGAL = Neutrophil gelatinaseassociated lipocalin; KIM-1 = kidney injury molecule-; AUC-ROC= area under the receiver operating characteristic curve
15 BIOMARKER(TIMP2-IGFBP7)KINETICS AND VANCOMYCIN EXPOSURE Ostermann M et al. Crit Care Med 2018: epub ahead of print
16 HYPERVIGILANCE/SURVEILLANCE PREVENTION IN PEDIATRIC, NON-ICU PATIENTS Development and refinement of a predictive AKI trigger with the goal of reducing AKI severity Knowledge for alert 3 nephrotoxins on the same day IV aminoglycoside for 3 days Recent: vancomycin for 3 days Pharmacist managed alert -outside of workflow and advice provided to practitioner Evidence of AKI Pediatric RIFLE criteria; no urine evaluation Risk: ecrcl decrease by 25% Injury: ecrcl decrease by 50% Failure: ecrcl decrease by 75% 1-yr: 42% decrease in AKI intensity with a reduction in days in AKI per 100 exposure days 3-yr: Results sustained with a 31% AKI intensity decrease and a 64% AKI rate decrease Goldstein SL et al. Pediatrics 2013;132:e756 Kirkendall ES et al. Appl Clin Inform 2014;5:313 Goldstien SL Kidney Int 2016;90:212
17 CHANGE SERUM CREATININE TO BIOMARKER MONITORING Adults? ICU patients? We already monitor serum creatinine regularly Alert 3 nephrotoxins Pharmacists evaluate alert -repeat, patient already has AKI Pharmacists order biomarker test and inform physician Pharmacists aid in interpretation and makes medication management recommendations QI- evaluate medication recommendations made, AKI severity, days of AKI and AKI incidence Frazee E, Voils S, Kane-Gill SL. Pharmacotherapy (in press).
18 CASE: A.B. 74 y.o. male admitted for septic shock due to a urinary tract infection (UTI) PMH: Alcoholic cirrhosis, stroke with hemiparesis and urethrocutaneous fistula with recurrent UTIs Fluids, vasopressors, cultures were drawn Starting piperacillin/tazobactam, gentamicin, vancomycin Renal assessment Serum creatinine (SCr) 0.8 mg/dl (egfr 92 ml/min) Urine output (UOP) 20 ml/h x 4h (0.25 ml/kg/hr)
19 WHAT STATEMENT BEST CHARACTERIZES THE USE OF TIMP-2 * IGFBP7 IN A.B.? A. TIMP-2 - IGFBP7 is not indicated for use in A.B. given his baseline risk for AKI B. TIMP-2 - IGFBP7 is indicated in A.B. to estimate GFR for renally-dosed medications C. TIMP-2 - IGFBP7 is indicated in A.B. and a level >2.0 would justify holding gentamicin and/or other nephrotoxins D. TIMP-2 - IGFBP7 is indicated in A.B and requires daily monitoring to optimize medication use
20 CASE: A.B. Clinical Stratification Low Risk High Risk Very High Risk TIMP-2 _ IGFBP7 Laboratory Stratification 0.3 > 0.3 to 2.0 > 2.0 Follow SCr/UOP, consider volume replacement, nephrotoxic antibiotics benefit > risk, reevaluate in 12-hours Follow SCr/UOP, urinalysis, evaluate fluid status and perfusion, critically determine whether gentamicin or vancomycin or this antibiotic combination is needed Consult nephrology, antibiotic combination risk > benefit, consider fluids and vasopressors, more closely monitor and adjust doses
21 OPERATIONAL ISSUES FOR IMPLEMENTING ALERT AND BIOMARKER Factors Stakeholder Support Institutional Approval Alert Development Engaging the Patient Care Team Education Cost Considerations Considerations Determining the high risk, target patient population for this intervention requires communication and support from stakeholders and key thought leaders Institutional approvals may be necessary?use a commercially available biomarker or biomarkers in development?outcome evaluation of biomarker Wait in the queue Use clinical decision support external to, but works with EMR- Theradoc Revise knowledge to reduce noise Efforts/workload of physicians, pharmacists, nurses and laboratory services need to be considered for rapid ordering of a biomarker test. Education for the team members regarding ordering and interpreting the biomarker test results More to come. Frazee E, Voils S, Kane-Gill SL. Pharmacotherapy (in press).
22 COST OF AKI $60,000 $50,000 $40,000 $30,000 $20,000 $10,000 Cost of AKI in CTICU patients Total Costs Incremental Costs $0 BigpAK - One ICU day LOS reduction in intervention about a $2400 (US) savings Averting or reducing AKI severity in one patient could result in cost savings Budget impact models and economic evaluations are needed Dasta JF et al. Nephrol Dial Transplant 2008;23: Collister D et al. Clin J Am Soc Nephrol 2017: 12:1733 Gocze I et al. Annals of Surgery 2017; epub ahead of print
23 Biomarkers for the Prevention of Drug Induced AKI (D-AKI) Sandra Kane-Gill, PharmD, MSc, FCCM, FCCP Associate Professor, University of Pittsburgh Critical Care Medication Safety Pharmacist, UPMC
Cystatin C: A New Approach to Improve Medication Dosing
Cystatin C: A New Approach to Improve Medication Dosing Erin Frazee Barreto, PharmD, MSc, FCCM Assistant Professor of Pharmacy and Medicine Kern Scholar, Center for the Science of Health Care Delivery
More informationCLINICAL DECISION SUPPORT FOR ME/ADE PREVENTION
CLINICAL DECISION SUPPORT FOR ME/ADE PREVENTION Sandra Kane-Gill, PharmD, MSc, FCCP, FCCM Associate Professor of Pharmacy, Critical Care Medicine and the Clinical Translational Science Institute, University
More informationNovel biomarker panel approach to renal assessment
Novel biomarker panel approach to renal assessment Professor of Critical Care Medicine, Medicine, Bioengineering and Clinical & Translational Science Vice Chair for Research Director, Center for Critical
More informationNephrotoxic Burden and Consequences Associated with Drug Induced AKI (D-AKI)
Nephrotoxic Burden and Consequences Associated with Drug Induced AKI (D-AKI) Sandra Kane-Gill, PharmD, MSc, FCCM, FCCP Associate Professor, University of Pittsburgh Critical Care Medication Safety Pharmacist,
More informationENDPOINTS FOR AKI STUDIES
ENDPOINTS FOR AKI STUDIES Raymond Vanholder, University Hospital, Ghent, Belgium SUMMARY! AKI as an endpoint! Endpoints for studies in AKI 2 AKI AS AN ENDPOINT BEFORE RIFLE THE LIST OF DEFINITIONS WAS
More informationCardiorenal Biomarkers and Heart Failure. Nicholas Wettersten, MD April 7 th, 2017
Cardiorenal Biomarkers and Heart Failure Nicholas Wettersten, MD April 7 th, 2017 Disclosures Still none, but looking for some Acute Kidney Injury Biomarkers 547 in 2015 4112 as of March 2017 Case 1 60
More informationLearning Objectives. How big is the problem? ACUTE KIDNEY INJURY
ACUTE KIDNEY INJURY Karen Innocent, DNP, RN, CRNP, ANP-BC, CMSRN Executive Director, Continuing Education Wolters Kluwer Health, Inc May 2016 Orlando FL Learning Objectives Identify the risk factors and
More informationSUPPLEMENTARY INFORMATION
Supplementary information S1 Studies of the effect of AKI duration on outcomes Study Study group (n) Criteria for AKI Definition of RR Outcomes Uchino et al. All patients admitted to (2010) 1 a university-affiliated
More informationAcute Kidney Injury (AKI) How Wise is Early Dialysis in Critically Ill Patients? Modalities of Dialysis
Acute Kidney Injury (AKI) How Wise is Early Dialysis in Critically Ill Patients? A common condition in ICU patients Associated with high mortality and morbidity Renal Replacement Therapy (RRT) is the cornerstone
More informationNEPHROCHECK. Know earlier. Intervene sooner. Avoid the danger and damage of Acute Kidney Injury.
Know earlier. Intervene sooner. Avoid the danger and damage of Acute Kidney Injury. 42% of critically ill patients with Sepsis develop AKI 1 2 SEPSIS AND ACUTE KIDNEY INJURY (AKI) ARE OFTEN CO-MORBIDITIES.
More informationPro-enkephalin and Renal Disease. Alan H. Wu, Ph.D. University of California, San Francisco 12 th Annual UCSD Biomarkers of Cardiac Disease
Pro-enkephalin and Renal Disease Alan H. Wu, Ph.D. University of California, San Francisco 12 th Annual UCSD Biomarkers of Cardiac Disease The presenter has received relevant grants and /or consulting
More informationBest Practices in Renal Dosing
Best Practices in Renal Dosing Bruce A. Mueller, PharmD Professor of Clinical Pharmacy University of Michigan College of Pharmacy Ann Arbor, MI LEARNING OBJECTIVES At the end of this lecture, the learner
More informationAcute Kidney Injury for the General Surgeon
Acute Kidney Injury for the General Surgeon UCSF Postgraduate Course in General Surgery Maui, HI March 20, 2011 Epidemiology & Definition Pathophysiology Clinical Studies Management Summary Hobart W. Harris,
More informationHeart Failure and Cardio-Renal Syndrome 1: Pathophysiology. Biomarkers of Renal Injury and Dysfunction
CRRT 2011 San Diego, CA 22-25 February 2011 Heart Failure and Cardio-Renal Syndrome 1: Pathophysiology Biomarkers of Renal Injury and Dysfunction Dinna Cruz, M.D., M.P.H. Department of Nephrology San Bortolo
More informationNGAL Connect to the kidneys
NGAL Connect to the kidneys Acute kidney injury (AKI) An imposing medical and diagnostic challenge >13 million AKI patients each year ~ 30% with fatal outcome Cardiac surgery > 1 million patients/year
More informationUpdate in. Acute Kidney Injury. Mark Devonald Consultant Nephrologist. Nottingham AKI Research Group
Update in Acute Kidney Injury Mark Devonald Consultant Nephrologist If you stay awake you might hear about Why AKI is important Some cases to illustrate some specific points A couple of updates on AKI
More informationThe 2012 KDIGO guidelines on Acute Kidney Injury-
The 2012 KDIGO guidelines on Acute Kidney Injury- Is there a need for an update and have the guidelines improved AKI prognosis? Norbert Lameire, MD,PhD Em prof of Medicine and Nephrology University Hospital
More informationAKI: definitions, detection & pitfalls. Jon Murray
AKI: definitions, detection & pitfalls Jon Murray Previous conventional definition Acute renal failure (ARF) An abrupt and sustained decline in renal excretory function due to a reduction in glomerular
More informationchanging the diagnosis and management of acute kidney injury
changing the diagnosis and management of acute kidney injury NGAL NGAL is a novel biomarker for diagnosing acute kidney injury (AKI). The key advantage of NGAL is that it responds earlier than other renal
More informationAccepted Manuscript. Epidemiology of Cardiac Surgery Associated Acute Kidney Injury. Eric AJ. Hoste, Wim Vandenberghe
Accepted Manuscript Epidemiology of Cardiac Surgery Associated Acute Kidney Injury Eric AJ. Hoste, Wim Vandenberghe PII: S1521-6896(17)30079-4 DOI: 10.1016/j.bpa.2017.11.001 Reference: YBEAN 968 To appear
More informationLas dos caras de la cretinina sérica The two sides of serum creatinine
Las dos caras de la cretinina sérica The two sides of serum creatinine ASOCIACION COSTARRICENSE DE MEDICINA INTERNA San José, Costa Rica June 2017 Kianoush B. Kashani, MD, MSc, FASN, FCCP 2013 MFMER 3322132-1
More informationDEFINITION, CLASSIFICATION AND DIAGNOSIS OF ACUTE KIDNEY INJURY
DEFINITION, CLASSIFICATION AND DIAGNOSIS OF ACUTE KIDNEY INJURY JOSÉ ANTÓNIO LOPES, MD, PhD Faculty of Medicine, University of Lisbon Department of Nephrology and Renal Transplantation Centro Hospitalar
More informationNovel Biomarkers in Critically Ill Patients and the Emergency Room
Novel Biomarkers in Critically Ill Patients and the Emergency Room Jay L. Koyner MD Section of Nephrology University of Chicago Research Funding: NIDDK, Abbvie, Astute, Argutus Outline Background / Pitfalls
More informationBiomarkers in Acute Kidney Injury
Biomarkers in Acute Kidney Injury Mark D. Okusa, M.D. Chief, Division of Nephrology Center for Immunity, Inflammation and Regenerative Medicine University of Virginia Health System Population incidence
More informationAutomated e-alerts & Integrated Clinical Decision Support in AKI
Automated e-alerts & Integrated Clinical Decision Support in AKI Sean M Bagshaw, MD, MSc Department of Critical Care Medicine, University of Alberta Canada Critical Care Forum, Toronto, Canada November
More informationBiomarcadores de lesión renal aguda AKI Biomarkers
Biomarcadores de lesión renal aguda AKI Biomarkers ASOCIACION COSTARRICENSE DE MEDICINA INTERNA San José, Costa Rica June 2017 Kianoush B. Kashani, MD, MSc, FASN, FCCP 2013 MFMER 3322132-1 Disclosure I
More informationDisclosures. Acute Kidney Injury. Outline. Do electronic alerts improve the care of patients with AKI? 5/9/2015
Disclosures Acute Kidney Injury Kathleen D. Liu, MD, PhD May 2015 Consultant: Achaogen, Chemocentryx, Durect, Z Pharma Clinical trials adjudication: Astute Funding: NIH Stockholder: Amgen Outline patients
More informationAccepted Manuscript. Looking to Prevent Acute Kidney Injury After Cardiac Surgery? Just Check the Urine.
Accepted Manuscript Looking to Prevent Acute Kidney Injury After Cardiac Surgery? Just Check the Urine. Daniel T. Engelman, MD, FACS, Michael J. Germain, MD PII: S0022-5223(18)32651-5 DOI: 10.1016/j.jtcvs.2018.08.119
More informationProfessor and Director. Children s Hospital of Richmond
Evaluation of AKI in term and premature infants Timothy E. Bunchman Professor and Director Pediatric Nephrology & Transplantation Children s Hospital of Richmond Virginia Commonwealth Univ. School of Medicine
More informationOptimal Use of Iodinated Contrast Media In Oncology Patients. Focus on CI-AKI & cancer patient management
Optimal Use of Iodinated Contrast Media In Oncology Patients Focus on CI-AKI & cancer patient management Dr. Saritha Nair Manager-Medical Affairs-India & South Asia GE Healthcare Context Cancer patients
More informationThe cell cycle biomarkers: promising research, but do not oversell them
CKJ REVIEW Clinical Kidney Journal, 2016, vol. 9, no. 3, 353 358 doi: 10.1093/ckj/sfw033 Advance Access Publication Date: 24 May 2016 CKJ Review The cell cycle biomarkers: promising research, but do not
More informationNGAL, a new markers for acute kidney injury
NGAL, a new markers for acute kidney injury Prof. J. Delanghe, MD, PhD Dept. Clinical Chemistry Ghent University Lecture Feb 8, 2011 Serum creatinine is an inadequate marker for AKI. > 50% of renal
More informationInterest of NGAL as early marker of Acute Kidney Injury CLINIQUES UNIVERSITAIRES SAINT-LUC
Interest of NGAL as early marker of Acute Kidney Injury P Wallemacq, Clinical Chemistry Department, M Mourad, Surgery and Abdominal Transplantation Cliniques universitaires St Luc, Université Catholique
More informationAKI Risk Assessment, Prevention & Early Detection. Dr Lui G Forni Worthing Hospital, Brighton & Sussex Medical School
AKI Risk Assessment, Prevention & Early Detection Dr Lui G Forni Worthing Hospital, Brighton & Sussex Medical School Risk Assessment Prevention Early Detection I won t tell you how many In slides 25 I
More informationHow and why to measure renal function in patients with liver disease?
ow and why to measure renal function in patients with liver disease? P. Angeli, Dept. of Medicine, Unit of Internal Medicine and epatology (), University of Padova (Italy) pangeli@unipd.it 10th Paris epatology
More informationUrinary biomarkers in acute kidney injury. Max Bell MD, PhD Karolinska University Hospital Solna/Karolinska Institutet
Urinary biomarkers in acute kidney injury Max Bell MD, PhD Karolinska University Hospital Solna/Karolinska Institutet Development of AKI-biomarkers Early markers of AKI, do we need them? GFR drop Normal
More informationAcute kidney injury definition, causes and pathophysiology. Financial Disclosure. Some History Trivia. Key Points. What is AKI
Acute kidney injury definition, causes and pathophysiology Financial Disclosure Current support: Center for Sepsis and Critical Illness Award P50 GM-111152 from the National Institute of General Medical
More informationA08 Using Kidney Biomarkers for AKI 2: Differential Diagnosis, Interventions and Prognosis
A08 Using Kidney Biomarkers for AKI 2: Differential Diagnosis, Interventions and Prognosis Kent Doi, MD, PhD Emergency and Critical Care Medicine, The Univ of Tokyo, Japan Using kidney biomarkers: Key
More informationDoppler ultrasound, see Ultrasonography. Magnetic resonance imaging (MRI), kidney oxygenation assessment 75
Subject Index Acidemia, cardiorenal syndrome type 3 146 Acute Dialysis Quality Initiative (ADQI) acute kidney injury biomarkers, see Acute kidney injury; specific biomarkers cardiorenal syndrome, see specific
More informationPreventing Acute Kidney Injury
Preventing Acute Kidney Injury Dr Andy Lewington MSc Clin Ed FRCP Consultant Nephrologist/Honorary Clinical Associate Professor Director of Undergraduate Medical Education Leeds Teaching Hospitals A.J.P.Lewington@leeds.ac.uk
More informationConflicts of Interest
Nephrotoxic Injury Negated by Just in time Action (NINJA) Stuart L. Goldstein, MD, FAAP, FNKF Director, Center for Acute Care Nephrology Nephrology & Hypertension The Heart Institute Conflicts of Interest
More informationRenal failure in sepsis and septic shock
Renal failure in sepsis and septic shock Dr. Venugopal Reddy. MD, EDIC, FCARCSI Associate Professor of Anesthesiology and Critical Care medicine Department of Anaesthesia and CCM Penn State College of
More informationNGAL. Changing the diagnosis of acute kidney injury. Key abstracts
NGAL Changing the diagnosis of acute kidney injury Key abstracts Review Neutrophil gelatinase-associated lipocalin: a troponin-like biomarker for human acute kidney injury. Devarajan P. Nephrology (Carlton).
More informationAcute kidney injury patterns and outcomes in low-risk versus high-risk critically ill patients admitted to the medical intensive care unit
Original article Acute kidney injury patterns and outcomes in low-risk versus high-risk critically ill patients admitted to the medical intensive care unit Cyriacus U Anaele MD, Gabriela Suarez MD, Sofia
More informationEVALUATION OF THE ROLE OF NEPHROTOXIC DRUGS IN CONTRAST INDUCED
EVALUATION OF THE ROLE OF NEPHROTOXIC DRUGS IN CONTRAST INDUCED NEPHROPATHY (CIN) Dr. SIRISHA.A POST GRADUATE KAMINENI INSTITUTE OF MEDICAL SCIENCES NARKETPALLY, TELANGANA INTRODUCTION Contrast-induced
More informationAcute Kidney Injury in Trauma. David Lee Skinner MBChB FCS(SA) Trauma Unit Inkosi Albert Luthuli Central Hospital KwaZulu Natal South Africa
Acute Kidney Injury in Trauma David Lee Skinner MBChB FCS(SA) Trauma Unit Inkosi Albert Luthuli Central Hospital KwaZulu Natal South Africa Acute Kidney Injury Acute Renal Failure RIFLE & AKIN RIFLE criteria
More informationWho should get a Biomarker Assessment? A focus on Biomarkers you may have at your hospital and risk scores
Who should get a Biomarker Assessment? A focus on Biomarkers you may have at your hospital and risk scores Jay L. Koyner MD Section of Nephrology Department of Medicine University of Chicago Disclosures
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationSAFETY IN THE CATH LAB How to Minimise Contrast Toxicity
SAFETY IN THE CATH LAB How to Minimise Contrast Toxicity Dr. Vijay Kunadian MBBS, MD, MRCP Senior Lecturer and Consultant Interventional Cardiologist Institute of Cellular Medicine, Faculty of Medical
More informationBiological markers for kidney injury and renal function in the intensive care unit Royakkers, A.A.N.M.
UvA-DARE (Digital Academic Repository) Biological markers for kidney injury and renal function in the intensive care unit Royakkers, A.A.N.M. Link to publication Citation for published version (APA): Royakkers,
More informationWORSENING OF RENAL FUNCTION AFTER RAS INHIBITION IN DECOMPENSATED HEART FAILURE: CLINICAL IMPLICATIONS
WORSENING OF RENAL FUNCTION AFTER RAS INHIBITION IN DECOMPENSATED HEART FAILURE: CLINICAL IMPLICATIONS George Bakris, MD, FASH, FAHA, FASN Professor of Medicine Director, Comprehensive Hypertension Center
More informationAugmented Renal Clearance: Let s Get the Discussion Flowing
Augmented Renal Clearance: Let s Get the Discussion Flowing Terry Makhoul, PharmD PGY-2 Emergency Medicine Pharmacy Resident University of Rochester Medical Center Strong Memorial Hospital Disclosures
More informationSupplementary Online Content
Supplementary Online Content Zarbock A, Schmidt C, Van Aken H, et al; for the RenalRIPC Investigators. Effect of remote ischemic preconditioning on kidney injury among high-risk patients undergoing cardiac
More informationChronic Renal Failure Followed by Acute Renal Failure
Chronic Renal Failure Followed by Acute Renal Failure Dr Emre Karakoç Çukurova Üniversity Department of Medical ICU Terminology Acute Kidney Injury Chronic Kidney Disease Acute Kidney Disease Acute kidney
More informationRationale for renal replacement therapy in ICU: indications, approaches and outcomes. Richard Beale
Rationale for renal replacement therapy in ICU: indications, approaches and outcomes Richard Beale RIFLE classification (ADQI group) 2004 Outcome AKIN classification Definition: Abrupt (within 48 hrs)
More informationAcute Kidney Injury. Amandeep Khurana, MD Southwest Kidney Institute
Acute Kidney Injury Amandeep Khurana, MD Southwest Kidney Institute 66 yr white male w/ DM, HTN, CAD admitted to an OSH w/ E Coli UTI on 7/24/16, developed E Coli bacteremia and Shock (on vaso + levo)
More informationBiomarkers for optimal management of heart failure. Cardiorenal syndrome. Veli-Pekka Harjola Helsinki University Central Hospital Helsinki, Finland
Biomarkers for optimal management of heart failure Cardiorenal syndrome Veli-Pekka Harjola Helsinki University Central Hospital Helsinki, Finland Presenter Disclosure Information V-P Harjola The following
More informationAcute Kidney Injury in The Acute Oncology Patient
Acute Kidney Injury in The Acute Oncology Patient Dr Andrew Lewington BSc MEd MD FRCP Consultant Renal Physician/Honorary Senior Lecturer Leeds Teaching Hospitals Definition Definitions and terminology
More informationAcute renal failure Definition and detection
Acute renal failure Definition and detection Pierre Delanaye, MD, PhD Nephrology, Dialysis, Transplantation CHU Sart Tilman University of Liège BELGIUM Definition Acute Renal Failure Acute Kidney Injury
More informationThe role of the Nephrologist in Acute Kidney Injury. Rebecca Brown Consultant Nephrologist Royal Liverpool University Hospital
The role of the Nephrologist in Acute Kidney Injury Rebecca Brown Consultant Nephrologist Royal Liverpool University Hospital Overview Impact of AKI Need for change Who needs a Nephrologist Are we making
More informationAcute kidney injury it personal! Spring 2018
Objectives Acute kidney injury it personal! Spring 2018 Mitzi Glover, PhD, MT(ASCP) mglov1@lsuhsc.edu Differentiate between acute kidney injury and chronic kidney disease Describe RIFLE, AKIN, and KDIGO
More informationSeverity and Outcome of Acute Kidney Injury According to Rifle Criteria in the Intensive Care Unit
BANTAO Journal 2010; 8 (1): 35-39 BJ BANTAO Journal Original Article Severity and Outcome of Acute Kidney Injury According to Rifle Criteria in the Intensive Care Unit Albana Gjyzari 1, Elizana Petrela
More informationWEEK. MPharm Programme. Acute Kidney Injury. Alan M. Green MPHM13: Acute Kidney Injury. Slide 1 of 47
MPharm Programme Acute Kidney Injury Alan M. Green 2017 Slide 1 of 47 Overview Renal Function What is it? Why does it matter? What causes it? Who is at risk? What can we (Pharmacists) do? How do you recognise
More informationAdding Insult to Injury. Marlies Ostermann Consultant in Nephrology & Critical Care Guy s & St Thomas Hospital, London
Acute Kidney Injury Adding Insult to Injury Marlies Ostermann Consultant in Nephrology & Critical Care Guy s & St Thomas Hospital, London Content 1. Brief review of AKI and its impact 2. Comments on the
More informationSAFE-T consortium. DIKI BM Summary Data Package. Novel clinical biomarkers of Drug-Induced Kidney Injury
1 SAFE-T consortium Summary Data Package Novel clinical biomarkers of Drug-Induced Kidney Injury The Drug induced kidney injury work package of Innovative Medicines Initiative SAFE-T Consortium Document
More informationInternational Journal of Advanced Research in Biological Sciences ISSN: Coden: IJARQG(USA) Research Article
International Journal of Advanced Research in Biological Sciences ISSN: 2348-8069 www.ijarbs.com Coden: IJARQG(USA) Research Article Serum Neutrophil gelatinase-associated lipocalin, a novel biomarker
More informationManagement of early chronic kidney disease
Management of early chronic kidney disease GREENLANE SUMMER GP SYMPOSIUM 2018 Jonathan Hsiao Renal and General Physician Introduction A growing public health problem in NZ and throughout the world. Unknown
More informationAn Introduction to Acute Kidney Injury (AKI) An Education Package for Healthcare Professionals in Medical Directorates
An Introduction to Acute Kidney Injury (AKI) An Education Package for Healthcare Professionals in Medical Directorates STH Acute Kidney Injury (AKI) Project 1 What is Acute Kidney Injury (AKI)? AKI is
More informationTIMP-2/IGFBP7 predicts acute kidney injury in out-of-hospital cardiac arrest survivors
Adler et al. Critical Care (2018) 22:126 https://doi.org/10.1186/s13054-018-2042-9 RESEARCH Open Access TIMP-2/IGFBP7 predicts acute kidney injury in out-of-hospital cardiac arrest survivors Christoph
More informationPlenary presentations 1
Wessex Cardiovascular Strategic Clinical Network Acute Kidney Injury Launch Event Wednesday 15 April 2015, 10.00 16.30 Plenary presentations 1 Wessex Acute Kidney Injury Clinical Forum Dr Mark Uniacke
More informationMinimizing the Renal Toxicity of Iodinated Contrast
Minimizing the Renal Toxicity of Iodinated Contrast Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCP Chief Academic and Scientific Officer St. John Providence Health System Detroit, MI USA Outline
More informationDiscovery & Validation of Kidney Injury Biomarkers
Dublin Academic Medical Centre Discovery & Validation of Kidney Injury Biomarkers Patrick Murray, MD, FASN, FRCPI, FJFICMI Professor, University College Dublin, Mater Misericordiae University Hospital,
More informationUne promenade dans l'épidémiologie de l'insuffisance rénale aiguë en quatre étapes
Une promenade dans l'épidémiologie de l'insuffisance rénale aiguë en quatre étapes Fernando Liaño Hospital Universitario Ramón y Cajal Madrid, España Genéve, 14-12-2012 Une promenade dans l'épidémiologie
More informationResearch Article Assessment of Cell-Cycle Arrest Biomarkers to Predict Early and Delayed Acute Kidney Injury
Disease Markers Volume 215, Article ID 158658, 9 pages http://dx.doi.org/1.1155/215/158658 Research Article Assessment of Cell-Cycle Arrest Biomarkers to Predict Early and Delayed Acute Kidney Injury Max
More informationSoto K, Coelho S, et al. Hospital Fernando Fonseca
SEPTIC INDUCED ACUTE KIDNEY INJURY Soto K, Coelho S, et al. Hospital Fernando Fonseca Introduction- Epidemiology RIFLE/AKIN Classification Scheme for AKI diagnosis 4.2 23 53 % Absence of other clear and
More informationCreatinine & egfr A Clinical Perspective. Suheir Assady MD, PhD Dept. of Nephrology & Hypertension RHCC
Creatinine & egfr A Clinical Perspective Suheir Assady MD, PhD Dept. of Nephrology & Hypertension RHCC CLINICAL CONDITIONS WHERE ASSESSMENT OF GFR IS IMPORTANT Stevens et al. J Am Soc Nephrol 20: 2305
More informationRENAL FUNCTION BIOMARKERS
HERNÁN TRIMARCHI HOSPITAL BRITÁNICO DE BUENOS AIRES ARGENTINA 2015 1 DISCLOSURES Served as a consultant and/or has received lecture honoraria from: ALEXION BRISTOL MYERS SQUIBB GENZYME NOVARTIS PFIZER
More informationPrimary Care Physicians and Clinicians. XXX on behalf of the Upper Midwest Fistula First Coalition. Chronic Kidney Disease (CKD) Resources
August 10, 2007 To: From: RE: Primary Care Physicians and Clinicians XXX on behalf of the Upper Midwest Fistula First Coalition Chronic Kidney Disease (CKD) Resources Caring for patients with chronic kidney
More informationSection Questions Answers
Section Questions Answers Guide to CKD Screening and Evaluation -Alec Otteman, MD Delaying Progression - Paul Drawz, MD, MHS, MS 1. Modifiable risk factors for CKD include: a. Diabetes b. Hypertension
More informationA Clinical Approach to Acute Renal Failure. Jeffrey J. Kaufhold, MD FACP July 2017
A Clinical Approach to Acute Renal Failure Jeffrey J. Kaufhold, MD FACP July 2017 Summary Impact of ARF on hospitalized patients Causes of Acute Renal Failure Differential Pre-Renal Intra-renal Post-Renal
More informationRCP : Regional Update in Medicine Acute Kidney Injury : A Renal Problem?
RCP : Regional Update in Medicine Acute Kidney Injury : A Renal Problem? Lui G Forni : Consultant Intensivist & Nephrologist Faculty of Health Sciences : University of Surrey Disclosures Research Funding
More informationAcute Kidney Injury Care in the Chronic Unit
Acute Kidney Injury Care in the Chronic Unit BONNIE B GREENSPAN WITH ASSIST FROM: DENISE MURCEK, JINA BOGLE, MARY SCHIRA, OCTOBER 5, 2017 Objectives At the completion of the session, engaged participants
More informationNothing to disclose 9/25/2017
Jessie O Neal, PharmD, BCCCP Critical Care Clinical Pharmacist University of New Mexico Hospital New Mexico Society of Health-System Pharmacists 2017 Balloon Fiesta Symposium Nothing to disclose 1 Explain
More informationAcute Kidney Injury 2
South West Cardiovascular Strategic Clinical Network Acute Kidney Injury 2 Audit review meeting 18/07/2014 Redwood Education Centre Author: Summary of results: Dr Preetham Boddana Consultant Nephrologist
More information9/25/2017. Nothing to disclose
Nothing to disclose Jessie O Neal, PharmD, BCCCP Critical Care Clinical Pharmacist University of New Mexico Hospital New Mexico Society of Health-System Pharmacists 2017 Balloon Fiesta Symposium Explain
More informationNorepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome
Norepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome Disclosure I have no conflicts of interest to disclose Name: Margarita Taburyanskaya Title: PharmD, PGY1 Pharmacy Practice Resident
More informationA New Approach for Evaluating Renal Function and Predicting Risk. William McClellan, MD, MPH Emory University Atlanta
A New Approach for Evaluating Renal Function and Predicting Risk William McClellan, MD, MPH Emory University Atlanta Goals Understand the limitations and uses of creatinine based measures of kidney function
More informationSPRINT: Consequences for CKD patients
SPRINT: Consequences for CKD patients 29 e Workshop Nierziekten Papendal 2018 December 12, 2018 MICHAEL ROCCO, MD, MSCE VARDAMAN M. BUCKALEW JR. PROFESSOR OF MEDICINE PROFESSOR OF PUBLIC HEALTH SCIENCES
More informationHigh urinary excretion of kidney injury molecule-1 predicts adverse outcomes in acute kidney injury: a case control study
Xie et al. Critical Care (2016) 20:286 DOI 10.1186/s13054-016-1455-6 RESEARCH High urinary excretion of kidney injury molecule-1 predicts adverse outcomes in acute kidney injury: a case control study Yuanyuan
More informationAcute Kidney Injury Is there a Best Practice?
Acute Kidney Injury Is there a Best Practice? M I T C H E L L R O S N E R, M D C h a i r m a n, D e p a r t m e n t o f M e d i c i n e U n i v e r s i t y o f V i r g i n i a H e a l t h S y s t e m Disclosures
More informationJMSCR Vol 06 Issue 12 Page December 2018
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v6i12.02 Original Research Article Fractional
More informationCan Big Data Drive Better Care for AKI? What is Big Data and How Can the EMR Work For You?
Can Big Data Drive Better Care for AKI? What is Big Data and How Can the EMR Work For You? AKI & CRRT 2018, March 8, 2018 Scott Sutherland Sean Bagshaw Perry Wilson Overview Introduction to Big Data as
More informationNeutrophil Gelatinase-Associated Lipocalin as a Biomarker of Acute Kidney Injury in Patients with Morbid Obesity Who Underwent Bariatric Surgery
Published online: October 31, 213 1664 5529/13/31 11$38./ This is an Open Access article licensed under the terms of the Creative Commons Attribution- NonCommercial 3. Unported license (CC BY-NC) (www.karger.com/oa-license),
More informationAcute Kidney Injury after Cardiac Surgery: Incidence, Risk Factors and Prevention
Acute Kidney Injury after Cardiac Surgery: Incidence, Risk Factors and Prevention Hong Liu, MD Professor of Clinical Anesthesiology Department of Anesthesiology and Pain Medicine University of California
More informationAcute Renal Failure (Clinics In Critical Care Medicine) READ ONLINE
Acute Renal Failure (Clinics In Critical Care Medicine) READ ONLINE If you are looking for a ebook Acute Renal Failure (Clinics in critical care medicine) in pdf format, then you've come to faithful site.
More informationAcute Kidney Injury IM Resident Lecture. Yongen Chang, MD, PhD Nephrology July 2018
Acute Kidney Injury IM Resident Lecture Yongen Chang, MD, PhD Nephrology July 2018 Objectives Epidemiology Definition and Staging Etiology and Diagnostic Approach Specific syndromes of AKI Treatment Biomarkers
More informationJMSCR Vol 04 Issue 12 Page December 2016
www.jmscr.igmpublication.org Impact Factor 5.244 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v4i12.19 Clinical Profile of Acute Kidney Injury:
More informationFluid Resuscitation in Critically Ill Patients with Acute Kidney Injury (AKI)
Fluid Resuscitation in Critically Ill Patients with Acute Kidney Injury (AKI) Robert W. Schrier, MD University of Colorado School of Medicine Denver, Colorado USA Prevalence of acute renal failure in Intensive
More informationAcute Kidney Injury. Arvind Bagga All India Institute of Medical Sciences New Delhi, India
Acute Kidney Injury Arvind Bagga All India Institute of Medical Sciences New Delhi, India What is AKI? Sudden loss of renal function, over hrdays, with derangement(s) in fluid balance, acid base & electrolytes
More informationAcute Kidney Injury in the ED
+ Acute Kidney Injury in the ED + Dr Eric Clark, MD FRCPC University of Ottawa Canada Canadian Association of Emergency Physicians + Outline 1. Diagnostic challenges 2. ED treatment 3. Contrast induced
More information